Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases

  • Giubilei C
  • Ingrosso G
  • D'Andrea M
 et al. 
  • 12


    Mendeley users who have this article in their library.
  • 20


    Citations of this article.


BACKGROUND: The efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in combination with whole brain radiotherapy (WBRT), for the treatment of 1-4 brain metastases, using a non invasive fixation of the skull, was investigated.

METHODS: Between 04/2001 and 01/2006 30 patients with 44 brain metastases underwent irradiation. Every patient received WBRT (10 x 3 Gy); 41/44 lesions received HSRT boost with a median dose fraction of 6 Gy, the fractionation schemes were 3 x 6 Gy and 4 x 8 Gy; a median total dose of 18 Gy was delivered to the tumor isocenter.

RESULTS: The median survival period was 9.15 months, the actuarial 1-year overall survival and freedom from new brain metastases were 36.6% and 87.9%, respectively; at univariate analysis Karnofsky Performance Status (KPS) was statistically significant (P = 0.05); the actuarial 1-year local control for the 41/44 lesions was 86.1%. No patient had acute or late complications.

CONCLUSIONS: HSRT as a concomitant boost during WBRT is a safe and well tolerated treatment for selected patients with brain metastases.

Author-supplied keywords

  • Brain metastases
  • Hypofractionated stereotactic radiotherapy
  • Local control
  • Prognostic factors
  • Radiobiology
  • Whole brain radiotherapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Cesare Giubilei

  • Gianluca Ingrosso

  • Marco D'Andrea

  • Michaela Benassi

  • Riccardo Santoni

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free